TY - JOUR
T1 - Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
AU - Salah, Husam M.
AU - Verma, Subodh
AU - Santos-Gallego, Carlos G.
AU - Bhatt, Ankeet S.
AU - Vaduganathan, Muthiah
AU - Khan, Muhammad Shahzeb
AU - Lopes, Renato D.
AU - Al’Aref, Subhi J.
AU - McGuire, Darren K.
AU - Fudim, Marat
N1 - Funding Information:
Dr. Bhatt reports consulting fees from Sanofi Pasteur, Verve Therapeutics, and Clarivate and is supported by the National Heart, Lung, and Blood Institute T32 postdoctoral training grant T32HL007604. Dr. Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa; speaker engagements with Novartis and Roche Diagnostics; and participates on clinical endpoint committees for studies sponsored by Galmed and Novartis. Dr McGuire has received honoraria for clinical trial leadership for Lilly US, AstraZeneca, Sanofi, Janssen, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Lexicon, Eisai, GlaxoSmithKline, CSL Behring, and Esperion, and for consultancy for Afimmune, AstraZeneca, Sanofi, Lilly US, Boehringer Ingelheim, Merck & Co, Pfizer, Novo Nordisk, Applied Therapeutics, and Metavant. Dr Fudim was supported by NHLBI K23HL151744 from the National Heart, Lung, and Blood Institute (NHLBI), the American Heart Association grant No 20IPA35310955, Mario Family Award, Duke Chair’s Award, Translating Duke Health Award, Bayer, and BTG Specialty Pharmaceuticals. He receives consulting fees from AxonTherapies, Bodyport, CVRx, Daxor, Edwards LifeSciences, Fire1, NXT Biomedical, Zoll, and Viscardia. All other authors report no conflict of interest.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022
Y1 - 2022
N2 - Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction (only empagliflozin and dapagliflozin have been investigated in this group so far), and chronic kidney disease. Prevention and reversal of adverse cardiac remodeling is one of the mechanisms by which SGLT2 inhibitors may exert cardiovascular benefits, especially heart failure-related outcomes. Cardiac remodeling encompasses molecular, cellular, and interstitial changes that result in favorable changes in the mass, geometry, size, and function of the heart. The pathophysiological mechanisms of adverse cardiac remodeling are related to increased apoptosis and necrosis, decreased autophagy, impairments of myocardial oxygen supply and demand, and altered energy metabolism. Herein, the accumulating evidence from animal and human studies is reviewed investigating the effects of SGLT2 inhibitors on these mechanisms of cardiac remodeling.
AB - Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction (only empagliflozin and dapagliflozin have been investigated in this group so far), and chronic kidney disease. Prevention and reversal of adverse cardiac remodeling is one of the mechanisms by which SGLT2 inhibitors may exert cardiovascular benefits, especially heart failure-related outcomes. Cardiac remodeling encompasses molecular, cellular, and interstitial changes that result in favorable changes in the mass, geometry, size, and function of the heart. The pathophysiological mechanisms of adverse cardiac remodeling are related to increased apoptosis and necrosis, decreased autophagy, impairments of myocardial oxygen supply and demand, and altered energy metabolism. Herein, the accumulating evidence from animal and human studies is reviewed investigating the effects of SGLT2 inhibitors on these mechanisms of cardiac remodeling.
KW - Cardiac remodeling
KW - Heart failure
KW - HFpEF
KW - HFrEF
KW - Mechanisms
KW - SGLT2 inhibitors
KW - SGLT2i
UR - http://www.scopus.com/inward/record.url?scp=85126311811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126311811&partnerID=8YFLogxK
U2 - 10.1007/s12265-022-10220-5
DO - 10.1007/s12265-022-10220-5
M3 - Review article
C2 - 35290593
AN - SCOPUS:85126311811
JO - Journal of Cardiovascular Translational Research
JF - Journal of Cardiovascular Translational Research
SN - 1937-5387
ER -